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There are four ErbB receptor family
members: ErbB1/EGF receptor, ErbB2,
ErbB3, and ErbB4. Under normal physi-
ological conditions, the activation of the
ErbB receptors is controlled by spatial
and temporal expression of their lig-
ands, EGF-related peptides. Ligand
binding induces the formation of multiple
combinations of ErbB receptor homo-
and heterodimers, resulting in activation
of the cytoplasmic kinase domain. This
in turn promotes the phosphorylation of
specific tyrosine residues, leading to the
stimulation of multiple signal transduc-
tion pathways (reviewed in Yarden and
Sliwkowski, 2001). ErbB2 is ligandless; it
functions as a coreceptor and is actually
the preferred partner for the other three
ErbB family members (Graus-Porta et
al., 1997). In a broad spectrum of carci-
nomas, including breast, ovarian, gas-
tric, and bladder, gene amplification
leads to ErbB2 overexpression, which
has been proposed to cause sponta-
neous dimerization and activation in the
absence of ligand. Experimental results
showing that high levels of ErbB2 trans-
form cultured cells as well as clinical
studies revealing that patients whose
tumors overexpress ErbB2 tend to have
a poor prognosis implied to many in the
cancer field that ErbB2 would be espe-
cially suitable as a therapeutic target.
While various approaches have been
taken to attain this goal, targeting
ErbB2’s extracellular domain with the
recombinant antibody trastuzumab
(Herceptin) has achieved the most
prominence.Trastuzumab is used for the
treatment of ErbB2-overexpressing
metastatic breast cancer patients. The
crystal structure of ErbB2 complexed
with another antibody, pertuzumab
(Omnitarg), described in this issue of
Cancer Cell (Franklin et al., 2004), sug-
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A new therapeutic antibody masks ErbB2 to its partners
In cancer cells, the ErbB2 receptor tyrosine kinase can be activated in two ways: by overexpression or by ligand-mediated
stimulation of another ErbB receptor. The ErbB2-targeting antibody trastuzumab (Herceptin) is used for treatment of
metastatic breast cancer patients whose tumors overexpress ErbB2. A new structural study in this issue of Cancer Cell
reveals how targeting ErbB2 with another antibody, pertuzumab (Omnitarg), prevents ligand-induced dimerization of ErbB2
with the other ErbB receptors. Pertuzumab’s novel mode of action might offer additional therapeutic opportunities for treat-
ment of tumors expressing ligand-activated ErbB2.
Figure 1. More than one way to inhibit ErbB2
A: In cells expressing low levels of ErbB2, HRG
binding to ErbB3 induces a switch from the
closed to the open state, exposing the
domain II dimerization arm, which leads to
the formation of ErbB2/ErbB3 heterodimers.
Binding of pertuzumab to ErbB2s domain II
prevents ligand-induced heterodimerization
and intracellular signaling (right side). In con-
trast, binding of trastuzumab to domain IV of
ErbB2 does not interfere with HRG-induced
ErbB2/ErbB3 association and thus does not
interrupt signaling activity and tumor cell
proliferation (right side). 
B: ErbB2-overexpressing cells show constitu-
tive ErbB2 and ErbB3 signaling. In vivo, 
both antibodies have antitumor activity,
which may reflect multiple mechanisms.
Trastuzumab prevents ErbB2 shedding
(Molina et al., 2001), induces downregula-
tion of ErbB2 and ErbB3 signaling, and inhibits
intracellular signaling (left side). While per-
tuzumab does not affect ErbB2 shedding,
other in vivo antitumor activities are still
unclear (indicated by the dotted line on the
right side). It is possible that pertuzumab
blocks the formation of ErbB2-containing
homo- and/or heterodimers leading to
tumor cell inhibition. N.B.: In ErbB2-overex-
pressing cells, the role of ErbB2s domain II
dimerization arm in the formation of dimers
has not yet been resolved.
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gests that in the future trastuzumab
might have to share the stage with per-
tuzumab. One might ask why we need
two therapeutic antibodies that target
the same receptor.The plethora of struc-
tural studies on ErbB receptors pub-
lished in the past few years, together
with the publication of Sliwkowski and
colleagues in this issue, reveal how
ErbB receptors are likely to dimerize and
why it might be better to have two anti-
bodies with different mechanisms of
action in the therapeutic arsenal.
Publications describing the crystal
structure of ErbB1, ErbB2, and ErbB3
extracellular regions (reviewed in
Burgess et al., 2003) have allowed new
insights into some intriguing questions
concerning the process of ligand-
induced receptor dimerization. Solving
the structure of ErbB2 complexed with
trastuzumab (Cho et al., 2003) and now
with pertuzumab (Franklin et al., 2004)
adds more information about domains
of this receptor that are important for
activity, both in the context of overex-
pression and ligand-induced activation.
Furthermore, these structures poten-
tially help us understand why there
might be differences in clinical response
to trastuzumab and pertuzumab.
The extracellular region of each
ErbB receptor consists of four domains
(I-IV) (Figure 1). Determination of the
structure of ligand bound ErbB1 has con-
firmed the importance of domains I and
III in peptide binding. Moreover, these
studies revealed that there is a direct
receptor-receptor interaction promoted
by the domain II loop, the so-called
dimerization arm. Interestingly, although
each ligand simultaneously contacts two
binding sites in the dimer, the ligand
does not span the dimer; thus, unlike
other transmembrane receptors, ErbB
dimerization is entirely receptor mediat-
ed. The structure of ErbB2’s extracellular
region is dramatically different from that
of ErbB1 and ErbB3. ErbB2 has a fixed
conformation that resembles the ligand-
activated state, i.e., the domain II-IV
interaction is absent, and the dimeriza-
tion loop in domain II is exposed. This
might help explain why ErbB2 is the pre-
ferred partner for the other ligand-acti-
vated ErbBs (Graus-Porta et al., 1997).
Furthermore, this structure explains why
no ligand has been found, since it pre-
dicts that ErbB2’s ligand binding site
would be buried within the structure and
not accessible for interaction.
Heregulin (HRG) binding to ErbB3
induces ErbB2/ErbB3 dimerization, and
pertuzumab has been shown to interfere
with heterodimer formation and down-
stream signaling (Agus et al., 2002). The
model of pertuzumab bound to ErbB2
presented by Franklin et al. provides
structural data that explain these obser-
vations. Pertuzumab binds to ErbB2 near
the center of domain II; binding is pre-
dicted to sterically block the region nec-
essary for ErbB2 dimerization with other
ErbBs. Pertuzumab does not block sig-
naling to ErbB3 when tested with ErbB2
mutants in residues predicted to be
important for this interaction, confirming
the structural data. In striking contrast to
pertuzumab, trastuzumab is unable to
block the formation of ErbB2-ErbB3
dimers (Franklin et al., 2004; Agus et al.,
2002), likely due to the fact that
trastuzumab binds ErbB2 in a region not
involved in dimerization (Cho et al.,
2003) (Figure 1A).
Do the differences in ErbB2 binding
have an impact on the antitumor activity
of the antibodies? In vivo results show
that they do. Pertuzumab but not
trastuzumab inhibits the growth of
tumors displaying low ErbB2 levels
(Agus et al., 2002), presumably due to its
ability to prevent autocrine- or paracrine-
produced ligands from inducing ErbB2-
containing heterodimers. Importantly,
pertuzumab also prevents in vivo growth
of tumors overexpressing ErbB2, the
same tumors that are sensitive to
trastuzumab (Figure 1B). So how is
pertuzumab functioning to block ErbB2-
overexpressing tumors? As experimen-
tally shown for trastuzumab (Clynes et
al., 2000), some of pertuzumab’s in vivo
antitumor activity is likely to be due to the
ability of the immunoglobulin G1 Fc
region to engage Fc γ receptors on
immune effector cells. However, per-
tuzumab may have additional activities.
On the one hand, it is possible that per-
tuzumab disrupts ErbB2-containing het-
erodimers, or higher-order receptor
oligomers, that form in the absence of
ligand. In fact, in some ErbB2-overex-
pressing tumor cells, the ErbB2/ErbB3
heterodimer functions as an oncogenic
unit; ErbB3 couples ErbB2 to the phos-
phatidylinositol 3-kinase signaling path-
way. It is currently not known how
ErbB2-ErbB3 heterodimers are formed
in the absence of a ligand; nevertheless,
in vitro, trastuzumab downmodulates
ErbB2, preventing ErbB3 transactivation
and tumor cell proliferation (Holbro et al.,
2003). As observed in cells with low
ErbB2, pertuzumab might mask ErbB2
to ErbB3 in tumor cells overexpressing
the receptor, something that awaits fur-
ther study. On the other hand, one can-
not exclude the possibility that
pertuzumab also prevents the formation
of ErbB2 homodimers. Unfortunately,
because of the predicted steric clash
(Franklin et al., 2004) or repulsive elec-
trostatic charges (Garrett et al., 2003),
ErbB2’s extracellular domain does not
homodimerize in solution. This has pre-
vented the resolution of the structure that
is presumably present in ErbB2-overex-
pressing tumors, precluding an under-
standing of pertuzumab’s impact on this
structure.
In the clinical setting, trastuzumab is
used for the treatment of breast cancer
patients with ErbB2-overexpressing
tumors; however, not all patients respond
to treatment. While other genetic defects
may allow these tumors to escape from
trastuzumab, another explanation may
be related to its mode of action. Indeed,
since trastuzumab does not prevent het-
erodimerization, the formation of ligand-
induced ErbB2-containing heterodimers
might still be possible, something that
would be unlikely with pertuzumab.Thus,
the addition of pertuzumab to the thera-
peutic arsenal should broaden the num-
ber of ErbB2-expressing tumors that can
be rationally targeted by antibodies to
include tumors with low levels of ligand-
activated ErbB2.
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In this issue of Cancer Cell, Rahman et
al. present data showing that high levels
of thymidylate synthase (TS), generated
by the transduction of immortalized
mouse cell lines with human TS cDNA or
by induction via a tetracyline-
responsive promoter, result
in transformation. By the cri-
teria of anchorage indepen-
dence and tumor formation in
nude mice, they show that a
high level of TS is capable of
transforming these cells to
malignancy. Thus, TS may be
considered a protooncogene
in that it is a normal protein
that functions as a positive
regulator of growth and is
converted to an oncogene by
overexpression.
Does a high level of TS
expression contribute to
tumor growth in patients?
Studies show that most
metastatic colorectal can-
cers have high levels of TS
mRNA and protein as com-
pared to primary colorectal
cancers and that primary col-
orectal cancers have higher
levels of TS as compared 
to normal colonic tissue.
Several studies also show
that patients with metastatic
colorectal cancer with tumors
that have high levels of TS
are less likely to respond to
treatment with 5-fluorouracil
than patients with lower lev-
els of this enzyme (reviewed
by Aschele et al., 2002; Bertino and
Banerjee, 2003; vanTriest and Peters,
1999). Only 20%–30% of patients have
what are considered low levels of this
enzyme, possibly related to deletion of a
portion of one of the alleles of chromo-
some 18, the location of the TS gene
(Bardot et al., 1991). Of interest, high TS
levels in the primary tumor have been
associated with a poor outcome, regard-
less of treatment (Edler et
al., 2002).
The high levels of TS in
some tumors have been
attributed to one of two
mechanisms: an increase in
gene copies of TS (only
5%–7%) or increased tran-
scriptional activation as a
result of the transcription fac-
tor E2F-1 (Degregori et al.,
1995). E2F-1 heterodimer-
izes with DP-1 and DP-2 and
activates the transcription of
genes encoding DNA syn-
thetic enzymes, including TS
(Banerjee et al., 1998).
Interestingly, E2F-1 has itself
been described as an onco-
gene or an oncogenic mes-
senger. Indeed, a recent
report indicates that most
metastatic colorectal tumors
overexpress E2F-1, associ-
ated with amplification of this
gene, raising the possibility
that TS is simply a player in
malignant transformation
attributed to E2F-1 (Iwamoto
et al., 2004).
A second question that
arises is whether or not the
oncogenic activity that is
attributed to TS is related to
its enzyme activity. TS is a
Thymidylate synthase as an oncogene?
A surprising finding in the report by Rahman et al. in this issue of Cancer Cell is that forced overexpression of human
thymidylate synthase transforms immortalized murine cells into a malignant phenotype. We discuss the possibility that
elevated levels of thymidylate synthase noted in some human malignancies may contribute to tumor progression and may
also reflect increased levels of its transcriptional activator E2F-1.
Figure 1. The thymidylate cycle
E2F-1 as the heterodimer E2F-1/DP-1 activates transcription of TS. The
other two enzymes of the thymidylate cycle are dihydrofolate reduc-
tase (DHFR) and serine hydroxymethyltransferase (SHMT). FH2,
dihydrofolate; FH4, tetrahydrofolate; CH2FH4, 5-10-methylene tetrahy-
drofolate.
